KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Acquisitions (2017 - 2025)

Elevance Health (ELV) has disclosed Acquisitions for 13 consecutive years, with -$33.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Acquisitions fell 100.9% to -$33.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$88.0 million, a 101.83% decrease, with the full-year FY2025 number at -$88.0 million, down 101.83% from a year prior.
  • Acquisitions was -$33.0 million for Q4 2025 at Elevance Health, down from -$1.0 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $3.7 billion in Q4 2024 to a low of -$81.0 million in Q3 2023.
  • A 5-year average of $577.7 million and a median of $20.0 million in 2022 define the central range for Acquisitions.
  • Peak YoY movement for Acquisitions: surged 170850.0% in 2021, then crashed 1350.0% in 2025.
  • Elevance Health's Acquisitions stood at $34.0 million in 2021, then decreased by 23.53% to $26.0 million in 2022, then tumbled by 169.23% to -$18.0 million in 2023, then soared by 20572.22% to $3.7 billion in 2024, then plummeted by 100.9% to -$33.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELV's Acquisitions are -$33.0 million (Q4 2025), -$1.0 million (Q3 2025), and -$50.0 million (Q2 2025).